OptiNose, Inc. (OPTN): Price and Financial Metrics


OptiNose, Inc. (OPTN): $1.89

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

OPTN POWR Grades

  • OPTN scores best on the Growth dimension, with a Growth rank ahead of 77.54% of US stocks.
  • OPTN's strongest trending metric is Stability; it's been moving up over the last 26 weeks.
  • OPTN's current lowest rank is in the Momentum metric (where it is better than 28.88% of US stocks).

OPTN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for OPTN is -1.06 -- better than only 4.91% of US stocks.
  • OPTN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 4.27% of US stocks.
  • OPTINOSE INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -29.96%, greater than the shareholder yield of only 15.59% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to OPTINOSE INC, a group of peers worth examining would be LPRO, DERM, BON, BLBX, and PWFL.
  • OPTN's SEC filings can be seen here. And to visit OPTINOSE INC's official web site, go to www.optinose.com.

OPTN Valuation Summary

  • OPTN's price/sales ratio is 1.9; this is 60.42% lower than that of the median Healthcare stock.
  • Over the past 63 months, OPTN's price/sales ratio has gone down 12.3.

Below are key valuation metrics over time for OPTN.

Stock Date P/S P/B P/E EV/EBIT
OPTN 2022-12-05 1.9 -2.0 -1.9 -3.6
OPTN 2022-12-02 1.9 -2.0 -1.9 -3.6
OPTN 2022-12-01 1.8 -1.9 -1.9 -3.6
OPTN 2022-11-30 1.9 -2.0 -2.0 -3.6
OPTN 2022-11-29 1.9 -2.0 -1.9 -3.6
OPTN 2022-11-28 1.9 -2.0 -1.9 -3.6

OPTN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OPTN has a Quality Grade of C, ranking ahead of 30.77% of graded US stocks.
  • OPTN's asset turnover comes in at 0.372 -- ranking 127th of 682 Pharmaceutical Products stocks.
  • ALT, FOLD, and RDUS are the stocks whose asset turnover ratios are most correlated with OPTN.

The table below shows OPTN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.372 0.861 -0.687
2021-03-31 0.317 0.854 -0.758
2020-12-31 0.282 0.847 -0.844
2020-09-30 0.258 0.832 -0.995
2020-06-30 0.251 0.840 -1.196
2020-03-31 0.225 0.841 -1.335

OPTN Price Target

For more insight on analysts targets of OPTN, see our OPTN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 1.4 (Strong Buy)

OPTN Stock Price Chart Interactive Chart >

Price chart for OPTN

OPTN Price/Volume Stats

Current price $1.89 52-week high $4.30
Prev. close $1.89 52-week low $1.55
Day low $1.80 Volume 964,600
Day high $1.91 Avg. volume 244,863
50-day MA $2.81 Dividend yield N/A
200-day MA $2.93 Market Cap 157.85M

OptiNose, Inc. (OPTN) Company Bio


OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. The company was founded in 2010 and is based in Yardley, Pennsylvania.


OPTN Latest News Stream


Event/Time News Detail
Loading, please wait...

OPTN Latest Social Stream


Loading social stream, please wait...

View Full OPTN Social Stream

Latest OPTN News From Around the Web

Below are the latest news stories about OPTINOSE INC that investors may wish to consider to help them evaluate OPTN as an investment opportunity.

Bucks County health care company expects to raise $50M

A Bucks County drug and delivery device developer expects to raise $50 million from a public stock offering set to close later this week. Optinose (NASDAQ: OPTN) of Yardley plans to sell 26.32 million shares of its common stock, along with warrants to purchase an equal amount of shares, at a combined price of $1.90 per share. The shares of common stock and warrants will be issued separately, but can only be purchased together in the offering, the company said.

Yahoo | November 22, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!

William White on InvestorPlace | November 21, 2022

Optinose Announces Pricing of Public Offering of Common Stock and Warrants

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 26,320,000 shares of its common stock and warrants to purchase 26,320,000 shares of its common stock at a combined public offering price of $1.90 per share and accompanying warrant, for gross proceeds of approximately $50 million to Optinose, before dedu

Yahoo | November 21, 2022

Optinose Announces Proposed Public Offering of Common Stock and Warrants

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. All shares of common stock and accompanying warrants to be sold in the offering will be sold by Optinose. In addition, Optinose is expected to gra

Yahoo | November 21, 2022

Analysts Are More Bearish On OptiNose, Inc. (NASDAQ:OPTN) Than They Used To Be

The latest analyst coverage could presage a bad day for OptiNose, Inc. ( NASDAQ:OPTN ), with the analysts making...

Yahoo | November 16, 2022

Read More 'OPTN' Stories Here

OPTN Price Returns

1-mo -45.53%
3-mo -49.60%
6-mo 2.16%
1-year 6.18%
3-year -78.13%
5-year -89.58%
YTD 16.67%
2021 -60.87%
2020 -55.10%
2019 48.71%
2018 -67.20%
2017 N/A

Continue Researching OPTN

Here are a few links from around the web to help you further your research on OptiNose Inc's stock as an investment opportunity:

OptiNose Inc (OPTN) Stock Price | Nasdaq
OptiNose Inc (OPTN) Stock Quote, History and News - Yahoo Finance
OptiNose Inc (OPTN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7787 seconds.